profit from every $100 of sales.
$0$100
Iovance Biotherapeutics
$7.76+1.70% today
+222.0% in 1 year
1-year low $2.131-year high $14.86
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Iovance Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $264 million in 2025, with -$391 million of profit last year.
SalesProfit
Iovance Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Iovance Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Iovance Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 1 | 164 | 264 | |
| 0 | 0 | 71 | 90 | |
| -399 | -461 | -395 | -398 | |
| -378 | -427 | -347 | -351 | |
| -396 | -444 | -372 | -391 | |
| -2.49 | -1.89 | -1.28 | -1.09 | |
| – | 13.1% | 43.2% | 34.3% | |
| – | -38,735.0% | -240.9% | -151.1% | |
| – | -37,345.4% | -226.8% | -148.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 664 | 780 | 910 | 913 |
| Cash | 232 | 115 | 116 | 163 |
| Total debt | 85 | 76 | 58 | 49 |
| Total liabilities | 164 | 196 | 200 | 215 |
| 500 | 585 | 710 | 699 | |
| 159 | 235 | 290 | 357 | |
| -53.9% | -55.1% | -40.6% | -42.1% | |
| -79.2% | -76.0% | -52.4% | -56.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -293 | -362 | -353 | -302 | |
| 20 | 22 | 11 | 34 | |
| -313 | -384 | -364 | -336 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 84 | 63 | 110 | 62 |
Valuation
- –
- –
- –
- 5.2×
- 13.6×
- –
- –
- -9.4%
- -10.9%
- 0.0%
Profitability
- 34.3%
- -151.1%
- -148.4%
- -114.4%
- -43.1%
- -49.1%
- -50.2%
- -38.2%
- -45.6%
- 100.1%
Growth
- +1,388.7%
- –
- +7.6%
- –
- +30.9%
Financial health
- -0.3×
- 0.07
- 5.1%
- –
- 3.20
- 3.15
- 0.31
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 10%of 946
Bottom 2%of 872
Bottom 12%of 986
What analysts expect
- Average price target
- $2.00
- Range
- $2.00 – $2.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.19 | -0.19 | +0.0% |
| Feb 24, 2026 | -0.18 | -0.22 | +18.2% |
| Nov 6, 2025 | -0.25 | -0.29 | +13.8% |
| Aug 7, 2025 | -0.33 | -0.29 | −13.8% |
| May 8, 2025 | -0.36 | -0.25 | −44.0% |
| Feb 27, 2025 | -0.26 | -0.26 | +0.0% |
| Nov 7, 2024 | -0.28 | -0.31 | +9.7% |
| Aug 8, 2024 | -0.34 | -0.37 | +8.1% |
News
Quant snapshot: Iovance Biotherapeutics and DiamondRock Hospitality Company lead top-rated names as Intact Financial and Fiserv Payments lagSeeking Alpha · Nov 2, 2026Dow, S&P 500, Nasdaq Futures Fall As Weak Tech Earnings Trigger Selloff: INTC, IOVA, SLS, AMZN Stocks In FocusYahoo Finance · Oct 30, 2026Can Iovance Stock Fall 50%?Yahoo Finance · Oct 29, 2026Dow, S&P 500, Nasdaq Futures Mixed After Fed Holds Rates Steady: GOOG, GOOGL, IOVA, MSFT, NOW In FocusYahoo Finance · Oct 29, 2026Apple, Meta, Iovance, Carnival, Fair Isaac, Bloom Energy, SpaceX, and More Stocks That Explain Today’s MarketYahoo Finance · Sep 29, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
40No pass
Philip Fisher
37No pass
Peter Lynch
49No pass
Joel Greenblatt
0No pass
Charlie Munger
32No pass
Terry Smith
29No pass
Questions about Iovance Biotherapeutics
Is Iovance Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Iovance Biotherapeutics AI analysis
What does Iovance Biotherapeutics do?
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. It is in Biotechnology.
Does Iovance Biotherapeutics pay a dividend?
No. Iovance Biotherapeutics does not pay a dividend at the moment.
Is Iovance Biotherapeutics stock halal?
Yes. Iovance Biotherapeutics passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Iovance Biotherapeutics stock done over the past year?
Up 222.0% over the past twelve months, to $7.76. It traded between $2.13 and $14.86 and is 47.8% below its high.
Who are Iovance Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Iovance Biotherapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.